Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-06-06 08:08 3349

Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-06-06 08:00 3320

Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-06-06 08:00 3110

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-06-01 08:00 3730

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-05-16 08:00 3992

Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment

SAN FRANCISCO and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2022-04-14 08:30 6108

Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022

SAN FRANCISCO and SUZHOU, China, April 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-04-11 08:14 2816

Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy

SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-04-06 12:43 3749

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022

SAN FRANCISCO and SUZHOU, China, April 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-04-04 08:00 4152

Innovent Announced 2021 Annual Results

* A Harvest Year with Product Revenue over RMB 4Bn * A Pipeline of 32 Valuable Assets with Late ...

2022-03-30 08:00 4371

Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor

SAN FRANCISCO and SUZHOU, China, March 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-03-29 08:10 3700

Innovent and Lilly Expand Strategic Partnership in Oncology

SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 28, 2022 /PRNewswire/ -- Innovent Biologics...

2022-03-28 08:00 6428

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-03-01 08:48 3499

Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor

SAN FRANCISCO and SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-02-24 08:00 4027

Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345

SAN FRANCISCO and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-02-21 08:00 3596

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-02-17 08:00 4875

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio

SAN FRANCISCO and SUZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-02-14 08:00 4467

FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission

SAN FRANCISCO, and SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administrati...

2022-02-11 10:44 4208

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy

SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-01-24 15:22 4607

Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022

SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-01-22 08:00 8803